Downregulation of Urinary microRNA-200c acts as a Promising Novel Bio-marker in the Diagnosis of Patients With Bladder Cancer

Hao Zi  
Huaihe Hospital of Henan University

Wen-Lin Tao  
Huaihe Hospital of Henan University

Lei Gao  
Huaihe Hospital of Henan University

Zhao-Hua Yu  
Huaihe Hospital of Henan University

Xiao-Dong Bai  
Huaihe Hospital of Henan University

Xiao-Dong Li (✉ yaouingwh@163.com)  
Henan University of Technology  https://orcid.org/0000-0002-2140-1968

Primary research

Keywords: MicroRNA-200c, Bladder cancer, Diagnosis

DOI: https://doi.org/10.21203/rs.3.rs-91603/v1

License: ☺ ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background

MicroRANs (miRNAs) have been reported to be involved in various human cancers. The aim of this study was to explore the diagnostic performance of urine miR-200c in bladder cancer.

Methods

Quantitative real-time polymerase chain reaction (qRT-PCR) method was applied to measure the relative expression of urine miR-200c in bladder cancer patients. The relationship between urine miR-200c level and clinicopathological factors was analyzed using $\chi^2$ test. The diagnostic capacity of urine miR-200c was calculated using the receiver operating characteristics (ROC) curve analysis.

Results

Urinary level of miR-200c was significantly reduced in bladder cancer patients compared with healthy controls ($P=0.000$). Furthermore, urine miR-200c expression was strongly correlated with histologic grade ($P=0.019$), tumor grade ($P=0.003$), and lymph node metastasis ($P=0.001$). ROC curve showed that urine miR-200c could distinguish bladder cancer patients from healthy controls with an area under the curve of 0.844. The cutoff value of 1.235, with the sensitivity of 89.0% and the specificity of 70.7% respectively.

Conclusion

Urine miR-200c may act as a noninvasive diagnostic biomarker for bladder cancer.

Background

Bladder cancer is one of most common malignancy in urinary system around the world [1]. It is featured by high recurrence, leading to poor outcomes and high mortality [2]. Currently, the standard of diagnostic tool for urinary bladder cancer is cystoscopy, but its clinical values are limited due to the invasive procedure, high cost and low efficacy in flat tumors like carcinoma in situ [3]. Non-invasive urine cytology, a convenient test, is used as an adjunct to cystoscopy [4]. It has high diagnostic specificity, but its sensitivity is unsatisfactory, especially for low-grade tumor [5]. Recently, there are numerous urine-based tests for early screening of bladder cancer, such as bladder tumor antigen (BTA), nuclear matrix protein 22 (NMP22) and FISH [6, 7]. However, none of them have been used in clinical guidelines [8]. Thus, it is of great value to identify non-invasive diagnostic markers for the detection of bladder cancer.

MicroRNAs (miRNAs) are small non-coding RNA molecules that play important roles in various biological processes through modulating the activity of specific mRNA [9]. Circulating miRNAs stably exist in a variety of body fluids including serum, plasma, saliva, pleural fluid and urine, and their abnormal expression may lead to human diseases, like cancer [10, 11]. Increasing evidences have showed that miRNAs are implicated in human carcinogenesis by functioning as either oncogenes or tumor
suppressors [12, 13]. The expression patterns of miRNAs show close association with tumor development and progression, which could be employed as predictive biomarkers and therapeutic targets [14]. MicroRNA-200c (MiR-200c), belonging to miR-200 family, is located on on chromosome 12p13 [15]. MiR-200c is a well-known tumor suppressor, and its downregulation has been observed in various cancers, such as breast cancer, gastric cancer, etc [16, 17]. In bladder cancer, it has been reported that the ectopic expression of miR-200c could inhibit bladder cancer cell proliferation and invasion in vitro [18]. MiR-200c may be involved in tumorigenesis of bladder cancer, which may be employed as an indicator for early screening of the malignant disease. However, there are few reports to address the issue.

In the present study, we examined the relative expression of urine miR-200c in bladder cancer patients, and analyzed the correlation of urine miR-200c expression with clinicopathological parameters of bladder cancer patients. We also investigated the diagnostic performance of urine miR-200c in bladder cancer patients.

**Methods**

*Patients and urine samples*

The study was approved by the Ethic Committee of Huaihe Hospital of Henan University. All the participants had signed the written informed consents.

A total of 109 patients with bladder cancer were obtained at the department of Huaihe Hospital of Henan University. Pathological grading of cases was based on the World Health Organization’s classification of urothelial neoplasms. Staging of bladder cancer was according to the classification of Union for International Cancer Control (UICC TNM). Details of the backgrounds and clinicopathological characteristics of the patients with bladder cancer were listed in **Table 1**. In addition, 96 age- and gender-matched healthy volunteers were recruited from the physical examination center of the hospital. All the healthy controls had no evidences for urological disorders or malignant diseases.

**Table 1.** The relationship of serum miR-200c expression with clinicopathological features in bladder cancer patients
| Features                  | Cases (n=109) | MiR-200c expression | $\chi^2$ | P-value |
|---------------------------|---------------|---------------------|----------|---------|
|                           | Low (n=56)    | High (n=53)         |          |         |
| Age (years)               |               |                     |          |         |
| <55                       | 44            | 23                  | 21       | 0.024   | 0.878   |
| ≥ 55                      | 65            | 33                  | 32       |         |         |
| Gender                    |               |                     |          |         |
| Male                      | 62            | 30                  | 32       | 0.514   | 0.473   |
| Female                    | 47            | 26                  | 21       |         |         |
| Smoking status            |               |                     |          |         |
| Non-smoker                | 71            | 35                  | 36       | 0.353   | 0.553   |
| Smoker                    | 38            | 21                  | 17       |         |         |
| Tumor size (cm)           |               |                     |          |         |
| <4                        | 75            | 43                  | 32       | 3.416   | 0.065   |
| ≥ 4                       | 34            | 13                  | 21       |         |         |
| Histologic grade          |               |                     |          |         |
| Low grade                 | 68            | 29                  | 39       | 5.514   | 0.019   |
| High grade                | 41            | 27                  | 14       |         |         |
| Tumor stage               |               |                     |          |         |
| T1-T2                     | 69            | 28                  | 41       | 8.773   | 0.003   |
| T3-T4                     | 40            | 28                  | 12       |         |         |
| Tumor types               |               |                     |          |         |
| NMIBC                     | 81            | 40                  | 41       | 0.502   | 0.479   |
| MIBC                      | 28            | 16                  | 12       |         |         |
| Lymph node metastasis     |               |                     |          |         |
| Absent                    | 77            | 32                  | 45       | 10.120  | 0.001   |
| Present                   | 32            | 24                  | 8        |         |         |

Notes: NMIBC: non-muscle invasive cancer; MIBC: muscle-invasive bladder cancer
From each subject preoperative urine sample (50ml) was collected in a sterile container and immediately refrigerated at the urology clinic. Within 2 hours urine samples were transported to the laboratory on ice. Each urine sample was assigned a unique identifying number before immediate laboratory processing. The sample was centrifuged at 3000g at 4°C for 10 minutes. The urine supernatant aliquots was decanted, centrifuged at 12000g for 10 minutes at 4°C and stored at -80°C before analysis at a genitourinary tissue bank.

**RNA extraction and quantitative real-time transcriptase polymerase chain reaction (qRT-PCR)**

Total RNA was extracted from urine samples using mirVana miRNA isolation kit (Ambion, Austin, TX, USA), according to the manufacturer’s directions. The concentration and purity of the RNA samples were measured using spectrophotometry, and the RNA samples with the OD260/280 value of 1.8-2.0 were used for the subsequent analysis. First strand cDNA was synthesized from the total RNA using a universal cDNA synthesis (Exiqon, Vedbaek, Denmark) in accordance with the manufacturer’s instructions. The relative expression of *miR-200c* was estimated using qRT-PCR method which was performed with SYBR Prime Script miRNA RT-PCR kit (Takara, Japan) in ABI 7500 real-time PCR system (Applied Biosystems, USA). RNU6B was used as the reference control. All of the samples were tested in triplicate. The relative level of *miR-200c* was calculated using the $2^{-\Delta\Delta Ct}$ method.

**Statistical analysis**

All the statistical analyses were performed using SPSS 18.0 software (SPSS software, Inc, IL, USA), and graphs were plotted using Origin 9.0. The Student’s *t* test was performed to compare urine *miR-200c* levels between bladder cancer patients and healthy controls. The relationship between urine *miR-200c* level and clinicopathological features was analyzed by $\chi^2$ test. Receiver operating characteristics (ROC) curves were established to evaluate the diagnostic performance of *miR-200c* in distinguishing bladder cancer patients from the controls. All statistical tests were two-sided and *P* values less than 0.05 were considered as statistical significance.

**Results**

*The relative expression of urine *miR-200c* in bladder cancer patients*

The expression level of *miR-200c* was detected using qRT-PCR in 205 urine samples (109 bladder patients and 96 controls). As shown in Figure 1, compared to healthy controls, urine *miR-200c* expression was significantly decreased in bladder cancer patients (*P*=0.000).

*The correlation between urine *miR-200c* expression and clinicopathological characteristics*

To identify the potential association between urine *miR-200c* expression and clinicopathological parameters in bladder cancer, the patients were divided into two groups based on the median value (0.82): low *miR-200c* expression group (n=56) and high *miR-200c* expression group (n=53). As indicated
in Table 1, urine miR-200c expression was dramatically associated with histologic grade \((P=0.019)\), tumor grade \((P=0.003)\), and lymph node metastasis \((P=0.001)\). Nevertheless, there was no relationships between urine miR-200c expression and other clinicopathological factors, such as age, gender, smoking status, or tumor types (all \(P>0.05\)).

**The diagnostic efficacy of urine miR-200c in bladder cancer patients**

ROC curve analyses revealed that urine miR-200c could use as a novel non-invasive biomarker to discriminate bladder cancer patients from healthy controls with an AUC value of 0.844 (95%CI: 0.789-0.898) (Figure 2). At a cutoff value of 1.235, the optimal sensitivity and specificity were 89.0% and 70.7% respectively.

**Discussion**

Bladder cancer is a heterogeneous disease with unpredictable clinical outcome. Several risk factors have been identified for bladder cancer, such as cigarette smoking, exposures to aromatic amines and 4,4'-methylenebis(2-chloroaniline) [19]. However, the molecular mechanisms underlying the bladder cancer development are still unclear. Nowadays, early screening and detection of bladder cancer remain a great challenge in clinic. Therefore, it is important to explore the effective bio-markers for early diagnosis of bladder cancer.

MiRNAs are a group of small endogenous RNAs, and they play regulatory role in gene expression at post-transcriptional level [9]. The expression profile of extracellular cell-free miRNAs are significantly correlated with tumor initiation, development and progression, which have been considered as promising biomarkers for cancer management [20]. The urinary miRNAs are stable at room temperature, and they could not be unaffected by multiple freeze-thaw cycles [21], indicating their properties as molecular biomarkers for cancer diagnosis and prognosis. Urine supernatant is a particularly desirable source of biomarkers for bladder cancer, with greatly convenient, reducing protein interference during RNA extraction and reflecting the status of diseases [22].

MiR-200c belongs to the miR-200 family which consists of miR-200a, miR-200b, miR-200c, miR-141 and miR-429 [23]. Accumulating evidences have demonstrated that miR-200 family has the capacity to regulate cancer transformation, growth, metastasis, and therapeutic response through targeting multiple signaling pathways, such as epithelial-mesenchymal transition (EMT), TGF-β signaling, PI3K/Akt signaling, Notch signaling, VEGF signaling, and NF-κB signaling [15, 24]. The expression pattern of miR-200c has been confirmed as a potential diagnostic and prognostic biomarker in a variety of tumors. For instance, Antolín et al. reported that circulating miR-200c was deregulated in breast cancer and showed close correlation with clinical characteristics of the patients that might serve as an independent prognostic indicator for the patients [25]. Meng et al. revealed that miR-200c level was involved in tumor progression and could distinguish malignant cases from benign ovarian tumors [26]. However, the clinical significance of miR-200c had been rarely reported in bladder cancer.
In the present study, qRT-PCR was applied to detect the relative expression level of \textit{miR-200c} in 205 urine samples collected from 109 bladder cancer patients and 96 healthy controls. Urine \textit{miR-200c} expression was obviously down-regulated in bladder cancer patients compared with healthy controls. Additionally, the decreased expression of \textit{miR-200c} was negatively correlated with histological grade, tumor stage, and lymph node metastasis. All the data suggested that \textit{miR-200c} as a tumor suppressor was involved in the progression and metastasis of bladder cancer patients. ROC analysis illustrated that urine \textit{miR-200c} was an useful biomarker for early detection of bladder cancer. The conclusion was consistent with the previous studies. Wu \textit{et al.} reported that the urinary \textit{miR-200} family levels were decreased in patients with bladder cancer [27]. The study carried out by Liu \textit{et al.} showed that \textit{miR-200c} could inhibit bladder cancer cells proliferation through down-regulating BMI-1 and E2F3 [28]. However, the possible underlying mechanisms for its participation in bladder cancer progression remained not clarify. Additionally, the sample size was relatively small that might influence the accuracy of our results. Therefore, further researches with a extended sample size will be performed to improve our conclusion.

**Conclusion**

In summary, urine \textit{miR-200c} expression is significantly decreased in bladder cancer patients, and negatively correlated with malignant disease progression. Urine \textit{miR-200c} may be a potential non-invasion biomarker for early diagnosis of bladder cancer.

**Abbreviations**

MicroRANs (miRNAs)

Quantitative real-time polymerase chain reaction (qRT-PCR)

receiver operating characteristics (ROC)

bladder tumor antigen (BTA)

nuclear matrix protein 22 (NMP22)

MicroRNA-200c (MiR-200c)

Union for International Cancer Control (UICC TNM)

**Declarations**

**Disclosure**
The authors report no conflicts of interest in this work.

**Ethics approval and consent to participate**
This study was supported by the Ethics Committee of Huaihe Hospital of Henan University and also has been carried out in accordance with the World Medical Association Declaration of Helsinki.
Consent for publication
The subjects had been informed the objective. Certainly, written consents were signed by every subject in this study.

Data availability
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Funding
No funding was received

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
H.Z. design of the work; WL.T. the acquisition, analysis, L.G. interpretation of data; ZH.Y. the creation of new software used in the work; XD.B., XD.L. have drafted the work or substantively revised it. All authors read and approved the final manuscript.

Acknowledgements
Not applicable.

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA: a cancer journal for clinicians 2015, 65(2):87-108.
2. Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M et al: EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. European urology 2017, 71(3):447-461.
3. Tiu A, Jenkins LC, Soloway MS: Active surveillance for low-risk bladder cancer. Urologic oncology 2014, 32(1):33 e37-10.
4. Sun M, Trinh QD: Diagnosis and staging of bladder cancer. Hematology/oncology clinics of North America 2015, 29(2):205-218, vii.
5. Yafi FA, Brimo F, Auger M, Aprikian A, Tanguay S, Kassouf W: Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer. Urologic oncology 2014, 32(1):27 e21-26.
6. Ganas V, Kalaitzis C, Sountoulides P, Giannakopoulos S, Touloupidis S: Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen. Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2012, 64(4):279-285.
7. Chou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, Grusing S, Selph S: Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis. Annals of internal medicine 2015, 163(12):922-931.
8. Schmitz-Drager BJ, Droller M, Lokeshwar VB, Lotan Y, Hudson MA, van Rhijn BW, Marberger MJ, Fradet Y, Hemstreet GP, Malmstrom PU et al: Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. *Urologia internationalis* 2015, 94(1):1-24.

9. Acunzo M, Croce CM: MicroRNA in Cancer and Cachexia–A Mini-Review. *The Journal of infectious diseases* 2015, 212 Suppl 1:S74-77.

10. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA: MicroRNAs in body fluids–the mix of hormones and biomarkers. *Nature reviews Clinical oncology* 2011, 8(8):467-477.

11. Hesse M, Arenz C: MicroRNA maturation and human disease. *Methods Mol Biol* 2014, 1095:11-25.

12. Acunzo M, Romano G, Wernicke D, Croce CM: MicroRNA and cancer–a brief overview. *Advances in biological regulation* 2015, 57:1-9.

13. Hayes J, Peruzzi PP, Lawler S: MicroRNAs in cancer: biomarkers, functions and therapy. *Trends in molecular medicine* 2014, 20(8):460-469.

14. Nana-Sinkam SP, Croce CM: MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use. *Genome biology* 2014, 15(9):445.

15. Mutlu M, Raza U, Saatci O, Eyupoglu E, Yurdusev E, Sahin O: miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance. *J Mol Med (Berl)* 2016, 94(6):629-644.

16. Kawaguchi T, Yan L, Qi Q, Peng X, Gabriel EM, Young J, Liu S, Takabe K: Overexpression of suppressive microRNAs, miR-30a and miR-200c are associated with improved survival of breast cancer patients. *Scientific reports* 2017, 7(1):15945.

17. Li M, Gu K, Liu W, Xie X, Huang X: MicroRNA-200c as a prognostic and sensitivity marker for platinum chemotherapy in advanced gastric cancer. *Oncotarget* 2017, 8(31):51190-51199.

18. Yuan D, Zheng S, Wang L, Li J, Yang J, Wang B, Chen X, Zhang X: MiR-200c inhibits bladder cancer progression by targeting lactate dehydrogenase A. *Oncotarget* 2017, 8(40):67663-67669.

19. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S et al: Epidemiology and risk factors of urothelial bladder cancer. *European urology* 2013, 63(2):234-241.

20. Schwarzenbach H, Nishida N, Calin GA, Pantel K: Clinical relevance of circulating cell-free microRNAs in cancer. *Nature reviews Clinical oncology* 2014, 11(3):145-156.

21. Yun SJ, Jeong P, Kim WT, Kim TH, Lee YS, Song PH, Choi YH, Kim IY, Moon SK, Kim WJ: Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. *International journal of oncolgy* 2012, 41(5):1871-1878.

22. Huang X, Liang M, Dittmar R, Wang L: Extracellular microRNAs in urologic malignancies: chances and challenges. *International journal of molecular sciences* 2013, 14(7):14785-14799.

23. Feng X, Wang Z, Fillmore R, Xi Y: MiR-200, a new star miRNA in human cancer. *Cancer letters* 2014, 344(2):166-173.

24. Humphries B, Yang C: The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. *Oncotarget* 2015, 6(9):6472-6498.
25. Antolin S, Calvo L, Blanco-Calvo M, Santiago MP, Lorenzo-Patino MJ, Haz-Conde M, Santamarina I, Figueroa A, Anton-Aparicio LM, Valladares-Ayerbes M: Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. *BMC cancer* 2015, **15**:297.

26. Meng X, Muller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H: Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. *Oncotarget* 2016, **7**(13):16923-16935.

27. Wang G, Chan ES, Kwan BC, Li PK, Yip SK, Szeto CC, Ng CF: Expression of microRNAs in the urine of patients with bladder cancer. *Clinical genitourinary cancer* 2012, **10**(2):106-113.

28. Liu L, Qiu M, Tan G, Liang Z, Qin Y, Chen L, Chen H, Liu J: miR-200c inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3. *Journal of translational medicine* 2014, **12**:305.